With its launch in August 2016, Zinbryta became the 14th disease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS) in the United States. The monoclonal antibody boasts solid efficacy, infrequent dosing, and a novel anti-inflammatory mechanism of action, but the potential for serious long-term side effects has led to a restrictive U.S. label. DRG’s launch-tracking series will examine how the perception and performance of Zinbryta evolves through one year postlaunch in an MS market that, on the one hand, is increasingly transformed by a growing array of DMTs with compelling risk-benefit profiles, but on the other hand, can and will support a clinical role for each new agent in treating a heterogeneous disease with a complex natural history.

What you will learn in this content:

  • What is U.S. neurologists’ awareness of and familiarity with Zinbryta, and what are their perceptions of the product?
  • Among prescribers, for which patients are they prescribing Zinbryta, what are the reasons for prescribing, and how satisfied are they with Zinbryta?
  • What are the promotional messages and activities that Biogen/AbbVie are employing in support of the Zinbryta launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Zinbryta tracking compared with other product launches in the MS market?

Methodology: ~75-100 U.S. neurologists complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback. In addition, ten surveyed specialists participate in a 30-minute follow-up qualitative interview.

Key drugs: Zinbryta, Lemtrada, Tysabri, Ocrevus, Gilenya, Tecfidera, Copaxone, beta-interferons

Key companies: Biogen, AbbVie, Sanofi Genzyme, Novartis, Teva, Roche/Genentech

Related reports: Emerging Therapies Zinbryta Wave 1, Emerging Therapies Lemtrada Waves 1-4

Table of contents

  • Multiple Sclerosis - Emerging Therapies - Zinbryta Launch Tracking Wave 2 (US)
    • Key Updates
      • June 2017
      • Key Findings
        • Benchmarking Zinbryta's Launch Success vs. Other Launched Drugs
          • Zinbryta Remains on Par with Benchmark DMTs on Certain Metrics, and Lower on Others at Six Months Postlaunch
          • Benchmarking Zinbryta Launch Success vs. Other Launched Drugs
        • Prescriber and Nonprescriber Profiles
          • Differences Between Zinbryta Prescriber and Nonprescriber Profiles
          • Differences Between Zinbryta Prescriber and Nonprescriber Profiles
        • Zinbryta Awareness and Perceptions
          • Unaided and Aided Awareness of Zinbryta
            • Unaided Awareness of Zinbryta Falls Behind Benchmark DMTs, but Aided Awareness is On Par
            • Unaided Awareness of Drugs Approved or Launched for the Treatment of RR-MS
            • Aided Awareness of Zinbryta
          • Familiarity with Zinbryta
            • Level of Familiarity with Zinbryta
            • Mean Level of Familiarity with Zinbryta
            • Aided Awareness of Zinbryta's Indication
            • Aided Awareness of the General Line of Therapy Recommendation for Zinbryta
            • Aided Awareness of Zinbryta's Dosing Interval
          • Sources of Familiarity with Zinbryta
            • Colleagues and Academic Publications Still Drive Product Familiarity, with Growing Support from Sales Representatives/MSLs
          • Initial Reaction to and Interest in Zinbryta
            • Neurologists' Initial Reaction to Zinbryta and Interest in Learning More Is Unchanged at Six Months Postlaunch
            • Zinbryta Product Profile
            • Zinbryta Information Requiring Additional Education
            • Initial Reaction to Zinbryta
            • Level of Interest in Learning More About Zinbryta
          • Impressions of Zinbryta
            • Zinbryta's Efficacy Stands Out and Remains Balanced with Its Risk
            • Unaided Advantages of Zinbryta
            • Unaided Disadvantages of Zinbryta
            • Rating of Zinbryta's Risk-Benefit Balance
            • Statement Agreements Regarding Zinbryta's Clinical Profile
            • Physician Quotes on Impressions of Zinbryta
          • Prescriber and Nonprescriber Profiles
            • Zinbryta Prescribers Appear More Experienced and Comfortable Managing Risk Than Nonprescribers
            • Differences Between Zinbryta Prescriber and Nonprescriber Profiles
        • Zinbryta Trial and Use
          • Willingness to Prescribe Zinbryta
            • Physicians Have Moderate Willingness to Prescribe Zinbryta in Wave 2
            • Willingness to Prescribe Zinbryta to MS Patients
            • Impact of Clinical and Nonclinical Attributes on Willingness to Prescribe Zinbryta
            • Enrollment in the Zinbryta REMS
            • Ease of Enrollment in the Zinbryta REMS
          • Number of Patients Currently Receiving Zinbryta
            • Most of the Current Zinbryta-Treated Patients Were Switched from an Injectable or Infusible DMT
            • Current DMT Patient Shares Among RR-MS Patients
            • Zinbryta Prescriber Base
            • Average Zinbryta Patient Volume
            • Zinbryta Discontinuation Rate
            • Reasons for Discontinuation of Zinbryta
            • Source of Business for Current Zinbryta Patients
            • Source Therapy for Current Patients Who Were Switched to Zinbryta
            • Number of Prior DMTs for Patients Switched to Zinbryta
            • Current Zinbryta Prescribing by Disease Classification
            • Reasons for Starting/Switching to Zinbryta
            • Zinbryta Follow-Up Visits
            • Zinbryta Treatment Response
            • Percentage of Patients Ever Treated with Zinbryta Who Have Experienced Select AEs
            • Top Three Obstacles to Prescribing Zinbryta More Frequently
            • Physician Quotes on Current Use of Zinbryta
            • Percentage of Neurologists Receiving a Patient Request for Zinbryta in the Past Month
            • Mean Number of Patients Requesting Zinbryta in the Past Month
            • Action Based on Specific Zinbryta Patient Requests in the Past Month
          • Reasons for Not Yet Prescribing Zinbryta
            • Lack of Familiarity and Safety Concerns Still Constrain the Zinbryta Prescriber Base
            • Reasons for Never Prescribing Zinbryta
          • Anticipated Zinbryta Use
            • Wave 2 Respondents Anticipate Zinbryta Will Gain Patient Share
            • Anticipated Timing for Zinbryta Prescribing Among Current Nonprescribers
            • Percentage of MS Patients Who Are Zinbryta Candidates by Disease Classification
            • Percentage of MS Patients Who Are Zinbryta Candidates by Treatment Situation
            • Current and Anticipated DMT Treatment Rate
            • Current and Anticipated Brand Allocation Among DMT-Treated RR-MS Patients
            • Physician Quotes on Anticipated Zinbryta Use
          • Zinbryta Performance on Key Attributes
            • Prescribers Reported High Overall Satisfaction with Zinbryta
            • Overall Satisfaction with Zinbryta Among Prescribers
            • Rating of Zinbryta's Performance on Clinical and Nonclinical Attributes
            • Physician Quotes on Zinbryta Performance on Key Attributes
        • Effectiveness of Face-to-Face Detailing for Zinbryta
          • Zinbryta Sales Representative Frequency and Reach
            • Contact with Zinbryta Sales Representatives Is Growing Slowly
            • Sales Representative Detailing Reach
            • Detailing Visits by Marketing Company
          • Satisfaction with Zinbryta Sales Representative
            • Neurologists' Satisfaction with Zinbryta Sales Representatives Remains High
            • Satisfaction with Zinbryta Sales Representatives
          • Zinbryta Message Recall
            • Early Zinbryta Messaging Includes Zinbryta's Indication and Drug Initiation Logistics
            • Unaided Zinbryta Message Recall During Recent Detail
            • Aided Zinbryta Message Recall During Recent Detail
        • Methodology
          • Primary Market Research Methodology
          • U.S. Region of Practice
          • Practice Setting
          • Practice Location
          • Years in Practice Post-Residency
          • Patient Allocation by MS Disease Classification
          • Current Drug Treatment Rate in RR-MS
        • Appendix
          • Abbreviations

      Author(s): Jonathan Searles

      Jonathan W. Searles is a Senior Director in the CNS/Ophthalmology unit at DRG, overseeing the neurology research stream. Prior to joining DRG, Mr. Searles received a B.A. degree, summa cum laude, from Brandeis University; during this time, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.


      Related Reports

      Multiple Sclerosis - Landscape & Forecast - Disease Landscape & Forecast

      The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will c...

      View Details

      Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2020

      The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment alg...

      View Details

      Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US)

      Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just...

      View Details

      Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Multiple Sclerosis 2020 – Main Report Dashboard (US)

      With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues...

      View Details